Dr.KarenChen said:Four weeks is the pharmacokinetics, not caution.
I disagree that the ladder is purely tolerability. The maintenance and regain data cluster at the top doses, so a ladder abandoned halfway leaves you outside the evidence base for the part that matters most — keeping it off.
fiona_VT said:I titrated faster than the label because I felt fine, hit a wall at the third step, and had to come back down — which I now think was the predictable…
Dose escalation anxiety for titration: I was terrified to move from 0.5mg to 1.0mg based on horror stories in this forum. But my actual experience? Slightly more appetite suppression, zero additional side effects.
Remember that the people posting about terrible side effects are a biased sample. Most people titrate up without drama — they just don't post about it because it's uneventful.
LibrarianMeg said:I disagree that the ladder is purely tolerability.
Coming at LibrarianMeg’s question from a different direction. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsOne thing that is still open after DadBodDave’s answer:
What the trials actually did with participants who could not tolerate a step, because that is the situation I am in and the protocol summaries skip it?
OP back with an update, since a thread like this is useless without one.
Update — I came back down one step, held for a month, then went up again and it was uneventful the second time. Same ladder, slower.